['non-small cell lung cancer']
['alectinib', 'docetaxel', 'pemetrexed']

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage
             IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is
             ALK-positive. ALK positivity must have been determined by a validated fluorescence in
             situ hybridization (FISH) test (recommended probe, Vysis ALK Break-Apart Probe) or a
             validated immunohistochemistry (IHC) test (recommended antibody, clone D5F3)

          -  Participant had received two prior systemic lines of therapy, which must have included
             one line of platinum-based chemotherapy and one line of crizotinib

          -  Prior CNS or leptomeningeal metastases allowed if asymptomatic

          -  Participants with symptomatic CNS metastases for whom radiotherapy is not an option
             will be allowed to participate in this study

          -  Measurable disease by RECIST Version 1.1 prior to the administration of study
             treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  For all females of childbearing potential, a negative pregnancy test must be obtained
             within 3 days before starting study treatment

        Exclusion Criteria:

          -  Participants with a previous malignancy within the past 3 years are excluded (other
             than curatively treated basal cell carcinoma of the skin, early gastrointestinal [GI]
             cancer by endoscopic resection or in situ carcinoma of the cervix)

          -  Participants who have received any previous ALK inhibitor other than crizotinib

          -  Any GI disorder that may affect absorption of oral medications
      